Literature DB >> 3548942

Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast.

J F McGurrin, M I Doria, P J Dawson, T Karrison, H O Stein, W A Franklin.   

Abstract

Cell proliferation was assessed in 33 invasive breast carcinomas by an immunoperoxidase procedure using the monoclonal antibody, Ki-67, which reacts with a nuclear antigen in proliferating cells. The antibody labeled a variable proportion of tumor cells ranging from 3% to 60%. High numbers of Ki-67-positive cells were found in tumors with high mitotic rates, high nuclear grade, high histologic grade, and in premenopausal women. Tumors with low and intermediate Ki-67 labeling rates often had high estrogen receptor content, whereas tumors with high Ki-67 labeling rates were usually estrogen receptor negative. These correlations are similar to those previously reported for other measurements of cell cycle kinetics such as thymidine labeling index and suggest that immunohistochemical staining of invasive breast carcinoma for the Ki-67 epitope may provide cell cycle information not otherwise readily available to the clinician and may be useful in assessing prognosis in carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3548942     DOI: 10.1002/1097-0142(19870515)59:10<1744::aid-cncr2820591012>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus.

Authors:  S Y Iftikhar; R J Steele; S Watson; P D James; K Dilks; J D Hardcastle
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

2.  Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma.

Authors:  Y Shoji; M Saegusa; Y Takano; M Ohbu; I Okayasu
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

3.  Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics.

Authors:  S A Swanson; J J Brooks
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

4.  Vascularity demonstrated by Doppler ultrasound and immunohistochemistry in invasive ductal carcinoma of the breast.

Authors:  E E Sterns; S SenGupta; F Saunders; B Zee
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Nucleolar grading of breast cancer. Comparative studies on frequency and localization of nucleoli and histology, stage, hormonal receptor status and lectin histochemistry.

Authors:  B Helpap
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

6.  Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears.

Authors:  V Kuenen-Boumeester; T H Van Der Kwast; H A Van Laarhoven; S C Henzen-Logmans
Journal:  J Clin Pathol       Date:  1991-03       Impact factor: 3.411

7.  Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer.

Authors:  D W Visscher; S Wykes; J Kubus; J D Crissman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

8.  Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features.

Authors:  P C Huettner; D S Weinberg; J M Lage
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

9.  Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.

Authors:  H Kreipe; P Alm; H Olsson; M Hauberg; L Fischer; R Parwaresch
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

10.  The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.

Authors:  R Schröder; K Bien; R Kott; I Meyers; R Vössing
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.